Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Laser opens door to better burn scar treatment

NCT ID NCT07660120

Symptom relief Sponsor: University of California, Davis Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 25, 2026 · Updated 4 times

Summary

This study tests whether adding a medication called 5-fluorouracil to a standard steroid treatment helps improve thick, raised burn scars more than the steroid alone. Both treatments are delivered through tiny holes made by a CO2 laser, which helps the medications reach deeper into the scar. Each participant's scar is split in half, with one side receiving both drugs and the other side only the steroid, allowing a direct comparison. The goal is to see if the combination reduces scar thickness and stiffness better.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
triamcinolone acetonide and 5-fluorouracil
What this could lead to
If adding 5-FU works better, it could offer a less painful, more effective way to treat thick burn scars.
What could go wrong
This is a small, early-stage study. The added medication may not improve results and could cause side effects like skin irritation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 65 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 89 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient with hypertrophic scarring secondary to burn injury * Ages 18-89 Exclusion Criteria: * Pregnant patients or patients of childbearing age, sexually active, and unwilling to utilize contraception * Children * Individuals that are cognitively impaired and unable to provide consent * Currently breastfeeding * Has taken oral retinoids within 6 months of study initiation * Prior laser or intralesional TAC/5-FU treatments for their hypertrophic scars * Active infection * Active malignancy * Known hypersensitivity to CO2 laser, TAC, or 5-FU * Known dihydropyrimidine dehydrogenase (DPD) deficiency (complete or partial), due to risk of systemic 5-FU toxicity * Systemic corticosteroid or immunosuppressive medication use * Intolerance to anesthesia * Known connective tissue disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Burn are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

burn Cicatrix, Hypertrophic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Burn CO2 laser in scars Hypertrophic scars Scar improvement by laser

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.